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When simultaneously testing multiple hypotheses, the usual approach in the
context of confirmatory clinical trials is to control the familywise error rate
(FWER), which bounds the probability of making at least one false rejection. In
many trial settings, these hypotheses will additionally have a hierarchical struc-
ture that reflects the relative importance and links between different clinical
objectives. The graphical approach of Bretz et al (2009) is a flexible and eas-
ily communicable way of controlling the FWER while respecting complex trial
objectives and multiple structured hypotheses. However, the FWER can be a
very stringent criterion that leads to procedures with low power, and may not
be appropriate in exploratory trial settings. This motivates controlling general-
ized error rates, particularly when the number of hypotheses tested is no longer
small. We consider the generalized familywise error rate (k-FWER), which is
the probability of making k or more false rejections, as well as the tail proba-
bility of the false discovery proportion (FDP), which is the probability that the
proportion of false rejections is greater than some threshold. We also consider
asymptotic control of the false discovery rate, which is the expectation of the
FDP. In this article, we show how to control these generalized error rates when
using the graphical approach and its extensions. We demonstrate the utility of
the resulting graphical procedures on three clinical trial case studies.
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1 INTRODUCTION
Inmodern clinical trials, it is increasingly common to test multiple hypotheses simultaneously. This multiplicity is driven
by evaluating multiple therapies in parallel, the identification of multiple subgroups and the measurement of multiple
endpoints. Given that these multiple hypotheses are assessed simultaneously, there is a strong emphasis on controlling
the total number or proportion of false positives (ie, type I errors) in some way. Indeed, for confirmatory clinical trials,
regulatory guidelines state that the familywise error rate (FWER) should be strongly controlled.1,2 This ensures that the
maximum probability of making at least one type I error is below some prespecified level (under any configuration of the
parameters being tested).
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The increase in multiplicity in clinical trials also tends to go hand-in-hand with an increase in the complexity of the
objectives and structure of the hypotheses tested. A key setting where this occurs is when measuring multiple endpoints
to answer distinct (but related) clinical questions. The corresponding hypotheses often fit naturally within a hierarchical
structure that reflects the relevant importance and links between the clinical questions that the trial aims to answer.
For example, in a trial with both a primary and secondary hypothesis, the trialist may only wish to test the secondary
hypothesis if the primary hypothesis is first rejected. More complex hierarchical structures can be formed as the number
of hypotheses increases.
Many methods have been developed for FWER control that respect complex trial objectives and multiple struc-
tured hypotheses. A highly flexible framework for doing so is the graphical approach to hypothesis testing, as pro-
posed independently by Bretz et al3 and Burman et al.4 In the framework of Bretz et al,3 vertices represent the
null hypotheses and weights represent the local significance levels, which are propagated through weighted, directed
edges. The resulting multiple testing procedure can be tailored to structured families of hypotheses with arbitrary
dependence between the hypotheses, and allows the visualization of complex decision strategies in an easily com-
municable way. Many well-known procedures for FWER control are special cases of the graphical approach, such as
the fixed sequence (or hierarchical) test,5 the Holm procedure,6 the Hochberg procedure,7 and several gatekeeping
procedures.8-10
However, controlling the FWER is a very stringent criterion, especially as the number of hypotheses increases. By
controlling the probability of even a single type I error, the power of FWER-controlling procedures can be very low, with
little chance of any of the individual hypotheses being rejected.While strong FWER control is appropriate in confirmatory
contexts, in exploratory trial settings such strict criterion may not be necessary. Indeed, as reflected in the FDA (2017)
guidance on multiple endpoints in clinical trials,1 exploratory analyses can be included in a trial to explore and generate
new hypotheses. Since such exploratory hypotheses will often be followed up with confirmatory testing, strict FWER
control at the exploratory stage is no longer necessary.
Westfall and Bretz11 expand on this argument, by categorizing the hypothesis tests in a typical clinical trial into fam-
ilies of “efficacy,” “safety,” and “exploratory” tests. For the efficacy family, the primary endpoints and main secondary
endpoints are the basis of regulatory approval and labeling, and hence require strong FWER control. However, there
may also be “lesser interest tests” (eg, multiple time point analyses), where FWER controlling methods are not needed.
Nonetheless, the authors note that some form of multiplicity adjustment would strengthen the claimsmade for this set of
tests. For the safety family, serious and known treatment-related adverse events (AEs) do not require multiplicity adjust-
ment (since type II errors are of much greater concern). However, for all other AEs, the authors state that there is a clear
need to recognize the multiplicity problem, and note that the use of the false discovery rate (FDR) may be more appropri-
ate here. Finally, for the family of exploratory tests (which may include both safety and efficacy tests), the authors state
that “standard multiplicity adjustment here seems unreasonable, as power will be very low,” and again recommend the
use of FDR controlling methods.
All this demonstrates that outside of the context of testing the primary and main secondary endpoints for regulatory
approval and labeling, strong FWER control may not be needed, even in confirmatory trials. Less stringent error rates can
then be used, wheremore than one false rejections are acceptable in order to increase the power of the trial. One approach
is to control the generalized FWER, or k-FWER. The k-FWER is the probability of making at least k false rejections, where
k ≥ 1. Clearly the FWER is a special case of the k-FWER when k = 1. A number of methods controlling the k-FWER
have been proposed, including step-up procedures12-15 and permutation-based procedures.16-18 Another approach is to
accept a certain proportion of false rejections, that is, to control the false discovery proportion (FDP). The FDP is closely
related to the well-known FDR,19 which is now a common error rate to control in experiments with a large number of
hypotheses, such as genomic studies. The FDR is the expected value of the FDP, that is, the FDR is the expected proportion
of errors among the rejected hypotheses. Although controlling the FDR controls the expectation of the FDP, in practical
applications the actual FDP might be far from its expectation.20 In the context of clinical trials with a relatively small
number (< 100) of hypotheses, this motivates control of the tail probability of the FDP and hence guaranteeing control
over the probability of having a high proportion of false discoveries. Somemethods for controlling the FDPhave previously
been proposed.12,17,21
In general, the various procedures proposed in the literature for generalized error rate control are not suitable for
structured hypothesis testing problems encountered in the context of clinical trials, as they do not respect the underlying
hierarchical structure of the testing strategy. In order to do so, in this article we show how to control both the k-FWER and
FDP (as well as asymptotic control of the FDR) when using the graphical approach of Bretz et al3 and its extensions. We
achieve this by modifying and applying the methodology for k-FWER and FDP control given by van der Laan et al22 and
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F I GURE 1 Graph showing a possible testing strategy for a diabetes
trial with a primary and secondary endpoint that tests two doses of a drug
against a placebo, as given in Maurer et al23
Romano and Wolf18 to the graphical framework. The performance of the resulting procedures are compared analytically
and through simulations in the context of various case studies.
The rest of the article is structured as follows. In Section 2, we introduce the basic notation and the graphical approach
to hypothesis testing. Section 3 shows how to modify the graphical approach to control the k-FWER, while Section 4
gives a further modification of the graphical approach to control the FDP as well as (asymptotic) control of the FDR.
Section 5 shows how to use the proposed procedures for a number of extensions to the graphical approach. We illustrate
the proposed methods using three case studies in Section 6, and conclude with a discussion in Section 7.
2 GRAPHICAL APPROACH TO HYPOTHESIS TESTING
Consider simultaneously testingmultiple null hypothesesH1,… ,Hm which are related in someway and so can be thought
of as a family of hypothesis tests. Since we are jointly testingmultiple hypotheses, there is a resultingmultiplicity problem
that we wish to take account of in the testing procedure. The standard approach for confirmatory clinical trials is to
control the FWER (in the strong sense) below some prespecified level 𝛼, where 𝛼 ∈ (0,1). That is, P(V > 0)≤ 𝛼 under any
configuration of true and false null hypotheses, whereV denotes the number of false rejectionsmade.We consider testing
H1,… ,Hm using the corresponding P-values P1,… ,Pm. LetM = {1,… ,m} denote the associated index set and assume that
the P-values associated with the true null hypotheses satisfy P(pi ≤u)≤u for any u∈ [0,1].
We now describe the graphical approach to hypothesis testing introduced by Bretz et al,3 which controls the FWER.
In this approach, the hypotheses H1,… ,Hm are represented by vertices, with associated weights denoting the sig-
nificance levels. Any two vertices Hi and Hj are connected by a directed edge with weight gij, which indicates the
fraction of the significance level 𝛼i which is propagated from Hi to Hj if Hi is rejected. If gij = 0 then there is no
propagation of the significance levels, and the edge can be dropped for convenience from the graphical visualiza-
tion. These gij form an m × m transition matrix G= (gij), which fully characterizes the propagation of significance
levels.
As an example, consider a trial in diabetes patients that compares two doses (a low dose and a high dose) of an exper-
imental drug against placebo, in terms of both a primary and secondary clinical endpoint. Since the primary endpoint is
more important than the secondary one, the trialist tests the primary hypothesis first; only if this is rejected is the sec-
ondary hypothesis then tested. Assuming that both doses are equally important, a possible testing strategy is shown in
the graph in Figure 1, as given in Maurer et al.23
Bretz et al24 proposed a graphical weighting strategy which allows the computation of the set of weights for any
intersection hypothesesHJ =
⋂
j∈JHj, J ⊆M. The graphical weighting strategy requires the specification of initial weights
wi(M), i∈M, for the global null hypothesis HM and the transition matrix G, with entries gij satisfying the regularity
conditions
0 ≤ gij ≤ 1, gii = 0 and
m∑
j=1
gij ≤ 1 for all i, j ∈ M. (1)
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Algorithm 7 in Appendix A1 reproduces the algorithm given in Bretz et al24 for calculating the weights wj(J), j∈ J,
which can then be used for testing the intersection hypothesis HJ .
Given these weights, a weighted multiple testing procedure can then be applied to each intersection hypothesis HJ ,
such as a weighted Bonferroni test, or a weighted parametric test if the joint distribution of the P-values is known.24
Applying a weighted Bonferroni test is the simplest option, and leads to the original Bonferroni-based graphical approach
for FWER control based on a shortcut procedure where them hypotheses can be tested sequentially, and hence requires
at mostm steps of the algorithm3 (see also Algorithm 8 in Appendix A1).
Adjusted P-values can also be calculated when using this graphical approach, which then allow the hypothesis tests to
be easily performed at any significance level 𝛼. More formally, the adjusted P-value Padjj for hypothesis Hj is the smallest
significance level atwhich one can reject the hypothesis using the givenmultiple test procedure.3 Algorithm9 inAppendix
A1 reproduces the algorithm given in Bretz et al3 for calculating adjusted P-values.
The R package gMCP25 provides functions and a graphical user interface to perform all of the calculations described
above.
3 GRAPHICAL APPROACHES FOR K-FWER CONTROL
Controlling the k-FWER at prespecified level 𝛼 implies that P(V > k) ≤ 𝛼, where V is the number of false rejections. The
generalized Bonferroni procedure controls the k-FWER:12,26 Reject any Hi for which pi ≤ k𝛼/m. Assuming known posi-
tive weights wi that satisfy
∑m
i=1 wi = 1, Romano and Wolf18 introduced the weighted generalized Bonferroni procedure:
Reject any Hi for which pi ≤ wik𝛼. If wi = 1/m for all i then this is equivalent to the unweighted version.
In order to extend the graphical approach for controlling the k-FWER, it is tempting to simply replace 𝛼 by k𝛼, in
analogy to the modification made for the generalized Bonferroni procedures. However, in general this does not control
the k-FWER for k> 1. As a counterexample, consider the Holm procedure withm hypotheses, which can be represented
as a graph with initial weights wi(M)= 1/m and gij = 1/(m − 1) for all i,j ∈M, i ≠ j. Using the graphical weighting strategy
(Algorithm 7), we have wi(I) = 1/|I| for all i ∈ I and I ⊆ M. Replacing 𝛼 by k𝛼 in the graphical approach (Algorithm 8)
is hence equivalent to a stepdown procedure where the ith smallest P-value is compared with the significance level 𝛼i =
k𝛼
m+1−i . However, since
k𝛼
m+1−i >
k𝛼
m+k−i for k > 1, the result of Theorem 2.3 in Lehmann and Romano
12 shows that this
procedure does not control the k-FWER. Hence, we turn to alternative procedures for k-FWER control.
3.1 Augmented graphical approach for k-FWER control
We first consider a simple method of controlling the k-FWER described in van der Laan et al [22, Procedure 1], which
can be applied to give a graphical approach for k-FWER control. The original method starts with an initial procedure that
controls the usual FWER, and then augments this by additionally rejecting the hypotheses associated with the smallest k
− 1 remaining (unrejected) P-values. These k − 1 additionally rejected hypotheses can be freely chosen, and so we aim to
respect the hierarchical structure of the underlying multiple testing problem and to avoid rejecting hypotheses with large
P-values. This results in the following augmented graphical approach for k-FWER control.
Algorithm 1 (Augmented graphical approach for k-FWER control).
(i) Apply the usual Bonferroni-based graphical procedure for FWER control given in Algorithm 8.
(ii) Let I denote the index set of any remaining (unrejected) hypotheses. If I is empty then stop; otherwise continue with
steps (ii) to (iv) of Algorithm 8 with 𝛼 replaced by 𝛿, until up to k − 1 additional (augmented) rejections are made.
Here 𝛿 ≥ 0 determines howmany of the “free” rejections we use, and can be set larger than 𝛼. In fact, we can even set
𝛿 large enough to ensure that k − 1 additional hypotheses are rejected, regardless of the observed P-values (see below). Of
course, this comes at the potential cost of rejecting hypotheseswithP-values close to 1 that are likely to be null. Conversely,
low values of 𝛿 mean that we are only willing to reject a hypothesis if it has reasonably substantial evidence against it.
In step (ii) of Algorithm 8, there may be a choice as to which of the hypotheses j ∈ I to reject. Since there can only be
a maximum of k additional rejections in step (ii) of Algorithm 1, the order in which hypotheses are rejected does matter
here. One sensible choice is to set j = argmini∈I{pi∕wi(I)}, which we use in the remainder of the article.
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F I GURE 2 The augmented graphical
approach for k-FWER control applied to the
diabetes trial. FWER, familywise error rate
The choice of 𝛿 can be data-dependent to ensure that (up to) k − 1 additional rejections are made. More explicitly, we
can increase 𝛿 so that one additional rejection is made, then if necessary increase 𝛿 until another additional rejection is
made, and so on. This allows an alternative formulation of the augmented graphical approach based on adjusted P-values,
which does not depend on an explicit choice of 𝛿.
Algorithm 2 (Adjusted augmented graphical approach for k-FWER control).
(i) Calculate the m adjusted P-values Padji corresponding to the usual Bonferroni-based graphical procedure for FWER
control, as detailed in Algorithm 9.
(ii) Reject all hypotheses Hi with Padji ≤ 𝛼.
(iii) Let I denote the index set of any remaining (unrejected) hypotheses. If I is empty then stop; otherwise order the remaining
hypotheses in nondecreasing order: Padj(1) ≤… ≤ p
adj
(|I|)
(iv) Additionally reject up to A = min(|I|, k − 1) hypotheses H(i) corresponding to Padj(1) ,… ,Padj(A)
If there are ties in the ordering in step (iii), they can be broken by choosing the hypothesis with the smallest index, for
example. Algorithm 1 will give the same rejections as Algorithm 2 for 𝛿 large enough. In addition, the R package gMCP25
can straightforwardly be used to implement Algorithm 1 in two stages corresponding to steps (i) and (ii). Hence, we focus
on Algorithm 1 in the rest of the article.
Example 1 (Example of the augmented graphical approach for k-FWER control:). Consider the graph of the diabetes
trial given in Figure 2, where we control the k-FWER for k = 2 with 𝛼 = .05. Suppose also that the P-values are given by
P1 = .01, P2 = .03, P3 = .02, P4 = .024.
In step (i) of Algorithm 1, the usual Bonferroni-based graphical procedure for FWER control would only rejectH1. The
updated graph (ie, removing nodeH1 and propagating the local significance levels) is then used in step (ii) of Algorithm 1,
with 𝛼 replaced by 𝛿. Supposing that 𝛿 = 0.5, we would then reject H2. At this point, we have made k − 1 additional
rejections, and so we stop testing having rejectedH1 andH2. Figure 2 demonstrates each step of the augmented procedure
graphically.
3.2 Generalized graphical approach for k-FWER control
As an alternative approach, we focus on Algorithm 7, which gives weights wj(J), j ∈ J, for any J ⊆M. As shown in Bretz
et al,3 these weights satisfy the monotonicity condition
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wj(J) ≤ wj(J′) for all J′ ⊆ J ⊆ M and j ∈ J′. (2)
Hence, we can apply the generic stepdownmethod for k-FWER control described in Romano andWolf [18, Algorithm
4.1]with theseweights to give the following generalized Bonferroni-based algorithm. Essentially, we simply set the critical
constants ĉn,K,i(1 − 𝛼, k) in their algorithm equal to wi(K), where K is used in step (iv) of Algorithm 3 below to index the
subsets including k− 1 of the previously rejected hypotheses. In what follows, we refer to this as the generalized graphical
approach for k-FWER control.
Algorithm 3 (Generalized graphical approach for k-FWER control).
(i) Set I =M.
(ii) Reject any Hi, i ∈ I for which pi ≤ wi(I)k𝛼
(iii) Let R = {i ∈ I:pi ≤ wi(I)k𝛼}. If |R| < k or |R| = |I| then stop; otherwise update I → I⧵R.
(iv) Reject any Hi, i ∈ I for which
pi ≤ min
J⊆R,|J|=k−1{wi(K) ∶ K = I ∪ J}k𝛼
If no such Hi exists then stop; otherwise let R′ be the indices of these rejected hypotheses.
(v) Update the sets I and R as follows:
I → I ⧵ R′
R → R ∪ R′
(vi) If |I| ≥ 1, go to step (iv); otherwise stop.
In Algorithm 3, at each step R is simply the set of indices of all the hypotheses that have been rejected previously, and
I is the set of indices of the remaining hypotheses M⧵R. The algorithm is in a similar spirit to the graphical weighting
strategy,24 in the sense that there is a separation between the weighting strategy and the graphical test procedure which
allows the generalization to k-FWER control.
In step (iii) of Algorithm 3, if |R| < k − 1 and |R| ≠ |I| then we can freely reject additional hypotheses so that a total of
(up to) k − 1 rejections are made, while still controlling the k-FWER, since the algorithm will stop at this step. In order
to respect the hierarchical structure of the underlying multiple testing procedure, and to avoid rejecting hypotheses with
large P-values, we propose the following subprocedure in step (iii) if |R| < k − 1:
1. Set I → I⧵R and follow steps (ii) to (iv) of the usual Bonferroni-based graphical procedure for
FWER control (Algorithm 8) with 𝛼 replaced by 𝛿, until up to k − 1 additional rejections have been
made.
As before, 𝛿 ≥ 0 determines how many of the “free” rejections we use, and hence can be set larger than 𝛼 or made
data-dependent so that (up to) k − 1 additional rejections are made.
Looking at Algorithm 3 as a whole, if k = 1, then once a hypothesis is rejected, it no longer plays a further role and
step (iv) above reduces to rejecting any Hi, i ∈ I, for which pi ≤ wi(I)𝛼. Hence, Algorithm 3 is equivalent to Algorithm 8
(the usual Bonferroni-based graphical approach for FWER control) in that both algorithms will lead to exactly the same
rejections when k = 1, assuming the same initial weights. When k > 1, however, the algorithm becomes more complex
and involves maximizing over subsets including k − 1 of the previously rejected hypotheses in step (iv). As noted by
Romano and Wolf,18 intuitively this is because when considering a set of unrejected hypothesis in Algorithm 3, we may
have already rejected (hopefully at most) k − 1 true null hypotheses. We do not know which of the rejected hypotheses
are true, and so we maximize over subsets including at most k − 1 of those hypotheses previously rejected. In Appendix
B1, we discuss the computational challenges of using Algorithm 3 for large values ofm, and show how to streamline and
operationalize the algorithm. However, in general these modified procedures only give asymptotic control of the k-FWER
as the sample size of the trial increases.
In Appendix B2, we give some examples of using the generalized graphical approach. We show how it reduces to
previous algorithms for k-FWER control as special cases, but also how it can have undesirable properties when the testing
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procedure has a hierarchical structure. The main problem (as demonstrated analytically in Example 4 of Appendix B2)
is that if a hypothesis Hj has fewer than k donors, its initial significance level will never increase, except for up to k − 2
hypotheses via the subprocedure in step (iii). Here, the donors of a hypothesis Hj are the hypotheses that donate (or
propagate) their significance levels toHj if they are rejected. Hence, the generalized graphical approach cannot effectively
propagate the significance levels through the graph. We will see further examples of this in the case studies given in
Section 6.
Example 2 (Example of the generalized graphical approach for k-FWER control:). We again consider the graph of
the diabetes trial given in Figure 1. We control the k-FWER for k = 2 with 𝛼 = .05, with the P-values this time given
by P1 = .01, P2 = .03, P3 = .02, P4 = .024. Applying the generalized graphical approach for k-FWER control gives the
following:
1. Set I = {1, 2, 3, 4}.
2. We reject anyHi, i ∈ I, for which pi ≤ wi(I)k𝛼. Here wi(I) are simply the initial weights and so w1(I) = w2(I) = 0.5 and
w3(I) = w4(I) = 0. Since p1 < 𝛼, p2 < 𝛼, H1 and H2 are rejected at this step.
3. We reject Hi, i ∈ I = {3, 4}, if pi ≤ min{wi({1, 3, 4}),wi({2, 3, 4})}. However, w3({1,3,4}) = w4({2,3,4}) = 0 and hence
neither H3 nor H4 can be rejected.
3.3 Existing power comparisons
Romano and Wolf16 argue that the augmented procedure is suboptimal compared with their generic stepdown method
for k-FWER control, since it can only reject at most k − 1 hypotheses more compared with a usual FWER-controlling
procedure, whereas Algorithm 3 can reject substantially more hypotheses. In their simulation study [16, Section 6], they
considered testing the means of a multivariate normal distribution with common correlation 𝜌, where the number of
hypotheses M = 50 or M = 400. They compared a number of different procedures for k-FWER control, but the relevant
power comparison for our context of graphical approaches is the one between the generalized Holm procedure and the
augmentedHolmprocedure. Their simulation results showed thatwhenM = 400, k= 10 and 𝜌≤ 0.5, the generalizedHolm
procedure can make a substantially higher number of rejections (up to twice as many) compared with the augmented
Holm procedure. However, whenM = 50 and k = 3, the augmented Holm procedure almost always had a higher number
of rejections than the generalized Holm procedure.
These findings are corroborated by the simulation results of Dudoit et al.27 They also considered testing the means
of a multivariate normal distribution, with the number of hypotheses M = 24 or M = 400. Through simulation,
they compared the augmented and generalized Holm and Bonferroni procedures, concluding that the augmented
approach tends to be more powerful than the generalized approach “for a broad range of models” [27, Section
6.2.1]. The largest gains in power were when the number of hypotheses was small and a large proportion of the
null hypotheses were true. However, for a large number of hypotheses (M = 400) and when 𝛼 was relatively large,
the generalized approaches was more powerful than the augmented approaches. In many clinical trials, we would
be in the setting with a smaller number of hypotheses, and so the augmented approach would be expected to be
more powerful. In our case studies in Section 6, we consider power comparisons beyond Bonferrroni or Holm based
methods.
4 GRAPHICAL APPROACHES FOR FDP AND (ASYMPTOTIC) FDR
CONTROL
In this section, we consider how to extend the graphical approach for FDP and (asymptotic) FDR control. More formally,
the FDP is defined as FDP = Vmax(R,1) , where R denotes the total number of rejections. The FDR is then the expectation
of the FDP. A multiple testing procedure controls the tail probability of the FDP at level 𝛼 if P(FDP > 𝛾) ≤ 𝛼, where 𝛾 ∈
[0,1) is a prespecified bound. This is also known as the tail probability for the proportion of false positives27 or the false
discovery exceedance.28 Note that setting 𝛾 = 0 results in control of the FWER at level 𝛼. In what follows, whenwe refer to
FDP control, we mean controlling this tail probability of the FDP, where we suppress the dependence on 𝛾 for notational
convenience.
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4.1 Augmented approach for FDP and FDR control
A simple method of controlling the FDP based on a FWER-controlling procedure is given by van der Laan [22, Proce-
dure 2]. This can be applied to give an augmented graphical approach for FDP control, in a similar way to that for k-FWER
control. A proof that FDP control holds can be found in van der Laan [22, Theorem 2].
Algorithm 4 (Augmented graphical approach for FDP control).
(i) Apply the usual Bonferroni-based graphical FWER procedure given in Algorithm 8. Let R denote the index set of the
rejected hypotheses.
(ii) Let I denote the index set of any remaining (unrejected) hypotheses. If I is empty, then stop.
(iii) Let D be the largest integer satisfying
D
D + |R| ≤ 𝛾
If D = 0 then stop; otherwise continue with steps (ii) to (iv) of Algorithm 8 with 𝛼 replaced by 𝛿, until up to D additional
(augmented) rejections are made.
Here 𝛿 ≥ 0 is a constant controlling howmany additional rejections are made. As before, 𝛿may be greater than 𝛼, and
can be set very large so that all D additional hypotheses are rejected. The choice of 𝛿 can also be data-dependent, giving
an alternative algorithm based on adjusted P-values, which does not depend on an explicit choice of 𝛿.
Algorithm 5 (Adjusted augmented graphical approach for FDP control).
(i) Calculate the m adjusted P-values Padji corresponding to the usual Bonferroni-based graphical procedure for FWER
control, as detailed in Algorithm 9.
(ii) Reject all hypotheses Hi with Padji ≤ 𝛼.
(iii) Let I denote the index set of any remaining (unrejected) hypotheses. If I is empty then stop; otherwise order the remaining
hypotheses in nondecreasing order: Padj(1) ≤… ≤ P
adj
(|I|)
(iv) Additionally reject up to A = min(|I|,D) hypotheses H(i) corresponding to Padj(1) ,… ,Padj(A)
If there are ties in the ordering in step (iii), they can be broken by choosing the hypothesis with the smallest index.
Algorithm 4 will give the same rejections as Algorithm 5 for 𝛿 large enough. In addition, the R package gMCP25 can
straightforwardly be used to implement Algorithm 4 in two stages corresponding to steps (i) and (iii). Hence, we focus on
Algorithm 4 in the remainder of the article.
Example 3 (Example of the augmented graphical approach for FDP control:). We continue the example of the diabetes
trial displayed in Figure 1, where this time we aim to control the FDP with 𝛼 = .05 and 𝛿 = 0.5. Suppose this time the
P-values are given by P1 = .01, P2 = .015, P3 = .02, P4 = .024. In step (i), the Bonferroni-based graphical procedure for
FWER control would reject H1 and H2. We then reject up to D additional hypotheses in step (iii), where D is the largest
integer satisfying D/(D + 2) ≤ 𝛾 . Hence if 0 ≤ 𝛾 < 1/3 we make D = 0 additional rejections, if 1/3 ≤ 𝛾 < 1/2 we make D =
1 additional rejection (reject H3), and if 𝛾 ≥ 1/2 we make D = 2 additional rejections (reject H3 and H4).
Although our focus in this article is on controlling the tail probability of the FDP, we note in passing that the aug-
mented procedure for FDP control at level 𝛼 automatically gives asymptotic control of the FDR at level 2𝛼. This follows
directly from van der Laan [22, Theorem 3]. Hence, applying the augmented graphical approach for FDP control given
in Algorithm 4 at prespecified level 𝛼 asymptotically controls the FDR at level 2𝛼. Lehmann and Romano12 showed
that FDP control at level 𝛼 also implies FDR control at level 𝛼∗ = 𝛼(1 − 𝛾) + 𝛾 . Hence, if 𝛼∗ < 2𝛼, which implies that
𝛾 < 𝛼/(1 − 𝛼), this bound can be used instead, while also yielding finite sample FDR control.
4.2 Generalized graphical approach for asymptotic FDP control
As an alternative method to control the FDP, we can directly apply the generic method for FDP control in Romano and
Wolf [18, Algorithm 8.1] to give the following graphical approach.
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Algorithm 6 (Generalized graphical approach for asymptotic FDP control).
(i) Let j = 1 and k1 = 1
(ii) Apply the kj-FWER procedure given in Algorithm 3, and let Rj denote the index set of the hypotheses it rejects.
(iii) If |Rj| < kj/𝛾 − 1, stop and reject all hypotheses rejected by the kj-FWER procedure. Otherwise, let j = j + 1 and kj = kj − 1
+ 1, then return to step (ii).
This algorithm was only proven in Romano and Wolf18 to give asymptotic FDP control, but they showed
empirically that it had good finite control of the FDP. However, since Algorithm 6 is based on the k-FWER generalized
graphical approach, the same potential problems as described in Appendix B2 will also apply. Finally, we again note
in passing that the result of Lehman and Romano12 shows that this procedure gives (asymptotic) FDR control at level
𝛼∗ = 𝛼(1 − 𝛾) + 𝛾 .
Example 4 (Example of the generalized graphical approach for FDP control:). We continue the example of the diabetes
trial displayed in Figure 1, where we aim to control the FDP with 𝛼 = .05 and 𝛿 = 0.5. Suppose the P-values are given by
P1 = .01, P2 = .015, P3 = .02, P4 = .024. In step (ii), applying the FWER procedure results in the rejection of H1 and H2.
Hence |R1| = 2 and we stop if 𝛾 < 1/3. If 𝛾 ≥ 1/3, then we apply the 2-FWER procedure, which again rejects H1 and H2.
Hence |R2| = 2 and we stop if 𝛾 < 2/3. If 𝛾 ≥ 2/3, then we apply the 3-FWER procedure, which rejects H1 and H2. Since
|R3| = 2 < 3/𝛾 − 1 for all 𝛾 < 1 we would stop at this step.
4.3 Existing power comparisons
Romano and Wolf16 argue that the augmented procedure for FDP control is suboptimal compared with their gen-
eralized method for FDP control, given that both are based on the k-FWER controlling procedures. In the simu-
lation results for FDP controlling procedures given in Dudoit et al27 and Romano and Wolf,16 the augmented and
generalized approaches as given above (Algorithms 4 and 6) are not directly compared for Holm (or Bonferroni)
based procedures. However, given their simulation results for k-FWER control, we might also expect the augmented
approach to have a higher power than the generalized approach when the number of hypotheses are small or
when the proportion of true null hypotheses is high. We consider such power comparisons in our case studies in
Section 6.
5 EXTENSIONS TO THE GRAPHICAL APPROACH
The original Bonferroni-based graphical approach of Bretz et al3 has been extended in a number of ways.29 These
extensions can be used in the augmented and generalized procedures for k-FWER and FDP control.
5.1 Entangled graphs
First, we consider the setting where it is desirable for the graphical procedures to have memory, in the sense that the
propagation of significance levels depends on their origin. To achieve this, we can define individual graphs for each
relationship and combine them afterward. This is known as an entangled graph, and the algorithm presented in Maurer
and Bretz30 gives an entangled Bonferroni-based graphical approach.
Hence, we can straightforwardly modify the augmented graphical approaches for k-FWER and FDR control for
use with entangled graphs. To do so, simply replace Algorithm 8 with the algorithm of Maurer and Bretz.30 For the
adjusted augmented graphical approaches, replace Algorithm 9 with the algorithm of Maurer and Bretz,31 which shows
how to calculate adjusted P-values for the entangled graph setting. Maurer and Bretz30 also showed how to calculate
the weights for any intersection hypothesis HJ , J ⊆ M, and this weighting strategy satisfies the monotonicity condi-
tion given in Equation (2). Hence, we can directly apply this weighting strategy to the generalized graphical approaches
for k-FWER and FDP control. We give an example of the use of entangled graphs in the case study described in
Section 6.2.
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5.2 Weighted parametric tests
All the procedures so far have been based on weighted Bonferroni tests, which can be conservative. As an alternative,
weighted parametric tests can be used if the joint distribution of the P-values pj, j ∈ J, are known for the intersection
hypothesis HJ . In this case, a weighted min-p test can be defined.32,33 This test rejects HJ if there exists a j ∈ J such that
pj ≤ cJwj(J)𝛼, where cJ is the largest constant satisfying
PHJ
(⋃
j∈J
{pj ≤ cjwj(J)𝛼}
)
≤ 𝛼.
If only some of the multivariate distributions of the P-values are known, then Bretz et al24 and Xi et al34
showed how to derive conservative upper bounds on this rejection probability, and hence determine a value
for cI .
The motonocity condition in this setting is
cJwj(J) ≤ cJ′wj(J′) for all J′ ⊆ J ⊆ M and j ∈ J′. (3)
which implies that rejection thresholds are alwaysmore liberal when fewer hypotheses are included in the set. In practice,
this condition is often violated when using weighted parametric tests.24 If this is the case, then it may be possible to
modify the weighting scheme so that Equation (3) holds.24,34 If the monotonicity condition does hold, then we can use
the weighted parametric tests directly for the augmented and generalized approaches for k-FWER and FDP control, with
the only change being that wi(I) is replaced by cIwi(I). For the adjusted augmented graphical approach, adjusted P-values
can be constructed for weighted parametric tests.34
5.3 Group sequential designs
The graphical approach can also be extended to group sequential designs with one or more interim analyses. Under mild
monotonicity conditions,Maurer andBretz35 proposed a graphical testing procedure formultiple hypotheses andmultiple
interim analyses. More formally, consider testing H1,… ,Hm in a group sequential trial at time points t = 1,… ,h. EachHi
has an associated error spending function ai(𝜅,y) with information fraction y and significance level 𝜅. The nominal signifi-
cance levels are denoted by ?̃?i,t(𝜅), which are the interim decision boundaries.We assume that these nominal levels satisfy
the monotonicity condition ?̃?i,t(𝜅′) ≥ ?̃?i,t(𝜅) for all 𝜅′ > 𝜅 (ie, the rejection boundaries are always higher when the total
error rate of the design is higher). These conditions hold for many spending functions, including O'Brien-Fleming and
Pocock boundaries.35 The algorithm presented in Maurer and Bretz35 gives a Bonferroni-based graphical test procedure
for group sequential designs.
The augmented graphical approaches for k-FWERandFDP control can hence be extended to apply to group sequential
designs: simply replace Algorithm 8 with the algorithm in Maurer and Bretz.35 For the adjusted augmented graphical
approach, replace Algorithm 9with the algorithm ofMaurer and Bretz,31 which shows how to calculate adjusted P-values
for the group sequential design setting.
6 CASE STUDIES
In this section, we compare and contrast the use of the algorithms for k-FWER and FDP control on three clin-
ical case studies covering a broad range of clinical trial applications. In Section 6.1 we revisit an exploratory
pharmacodynamic clinical trial to investigate the effect of drug activity at the GABA-A receptor in the brain.
In Section 6.2, we revisit a proof-of-concept trial investigating three doses of a new drug against a placebo
on multiple biological endpoints related to acute heart failure. Finally, in Section 6.3 we illustrate the pro-
posed approaches for the comparison of three therapies in a confirmatory clinical trial for heart failure
patients.
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F I GURE 3 Graph representing the testing strategy for the
pharmacodynamic study described in Ferber et al,36 with
modified initial weights. Here contrast TiDj compares the
change from baseline under dose j (j = 1,2,3) at time point i (i =
1,… ,5) to the corresponding change under placebo
6.1 Pharmacodynamic study
Our first case study is motivated by the exploratory pharmacodynamic clinical study reported by Ferber et al,36 which
explored the effect of drug activity at theGABA-A receptor in the brain asmeasured using a quantitative electroencephalo-
gram (qEEG). Three doses of the drug (0.25, 0.5, and 1 mg) were tested as well as a placebo. During the first 15 minutes
after the drug was given to each patient, qEEGmeasurements were taken and afterward subdivided into five time slices of
3 minutes duration. The analysis strategy used amixed effect linear model to obtain 15 contrasts to formally test. Contrast
TiDj compared the change from baseline under dose j (j = 1,2,3) at time point i (i = 1,… ,5) to the corresponding change
under placebo. Figure 3 shows the graph representing the hierarchical testing strategy used for these 15 hypotheses (with
modified initial weights, see below), and Table 1 gives the unadjusted P-values from the mixed effects linear model for
the 15 hypotheses.
Figure 3 shows that the hypotheses T4D3 and T5D2 each only have a single donor hypothesis (T5D3). Hence
if they have initial weights of zero (as in the original graph36), then they cannot be rejected by the generalized
graphical approach for k-FWER control with k = 2. This then means that no hypotheses can be rejected except for
T5D3. Therefore, we first set the initial weights for T4D3,T5D2, and T5D3 to 1/3, with all other weights set equal
to zero.
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Time
Dose T1 T2 T3 T4 T5
D1 0.7808 0.0600 0.0137 0.0724 0.0162
D2 0.9433 0.0053 6.5 × 10 − 6 2.8 × 10 − 6 9.1 × 10 − 8
D3 0.9993 1.0 × 10 − 5 1.7 × 10 − 11 4.2 × 10 − 12 8.1 × 10 − 13
TABLE 1 Table of P-values for
the pharmacodynamic study of Ferber
et al36
Procedure Rejected hypotheses
k-FWER
Generalized k = 1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
k = 2 T4D3,T5D2,T5D3
k = 3 T4D3,T5D2,T5D3
Augmented k = 1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
k = 2 T2D3,T3D2,T3D3,T4D1,T4D2,T4D3,T5D1,T5D2,T5D3
k = 3 T2D3,T3D1,T3D2,T3D3,T4D1,T4D2,T4D3,T5D1,T5D2,T5D3
FDP
Generalized 𝛾 = 0.1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
𝛾 = 0.2 T4D3,T5D2,T5D3
𝛾 = 0.3 T4D3,T5D2,T5D3
Augmented 𝛾 = 0.1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
𝛾 = 0.2 T2D3,T3D1,T3D2,T3D3,T4D1,T4D2,T4D3,T5D1,T5D2,T5D3
𝛾 = 0.3 T2D2,T2D3,T3D1,T3D2,T3D3,T4D1,T4D2,T4D3,T5D1,T5D2,T5D3
Abbreviations: FDP, false discovery proportion; FWER, familywise error rate.
TABLE 2 Rejected
hypotheses for the
pharmacodynamic study of Ferber
et al,36 with initial weights of 1/3
for T4D3,T5D2, and T5D3
Table 2 shows the resulting rejections for the generalized and augmented graphical k-FWER and FDP controlling
procedures, with 𝛿 = 1. Looking first at the k-FWER procedures, for k = 1 the generalized and augmented graphical
procedures both reject the same eight hypotheses, as would be expected. For k = 2 and k = 3, the augmented procedure
rejects 9 and 10 hypotheses, respectively. However, the generalized graphical procedure rejects fewer hypotheses when
k = 2 and k = 3, with only three rejections in both cases. For k = 3 this is because all hypotheses have fewer than three
donors and hence only those hypotheses with nonzero initial weights can be rejected. This is still the case when k = 2,
even though all hypotheses (except for T5D3) have two donors, showing that the generalized graphical procedure cannot
effectively propagate the significance levels through the graph.
There is a similar pattern for the FDP controlling procedures, which is expected given that they are based on the
k-FWER controlling procedures. For 𝛾 = 0.1 the generalized and augmented graphical procedures give the same eight
rejections, which are also the same as the k-FWER controlling procedures when k = 1. For 𝛾 = 0.2 and 𝛾 = 0.3, the
augmented procedure rejects 10 and 11 hypotheses, respectively. However, again the generalized graphical procedure
rejects fewer hypotheses for the larger values of 𝛾 = 0.2 and 𝛾 = 0.3, with only three hypotheses rejected. These are the
same rejections as the generalized k-FWER controlling procedure for k > 1, because kj > 1 in Algorithm 6.
We also consider the setting where all 15 hypotheses have initial weight of 1/15. Table 3 shows the resulting rejections
for the generalized and augmented graphical k-FWER and FDP controlling procedures, with 𝛿 = 1. With these new ini-
tial weights, the k-FWER controlling procedures both reject the same seven hypotheses when k = 1 and the same eight
hypotheses with k = 2. This shows how the generalized graphical procedure can benefit with nonzero initial weights.
However, for k = 3 the augmented procedure rejects one more hypothesis (T5D1) than the generalized graphical proce-
dure. This is because all hypotheses have fewer than three donors, and hence the weights for the generalized graphical
procedure cannot increase—that is, there is no propagation of the significance levels.
Similarly, the FDP controlling procedures both reject the same seven hypotheses when 𝛾 = 0.1 and the same eight
hypotheses when 𝛾 = 0.2, which are also the same rejections as the k-FWER controlling procedures when k = 1 and
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TABLE 3 Rejected hypotheses for
the pharmacodynamic study of Ferber
et al36 with initial weights of 1/15 for
each hypothesis
Procedure Rejected hypotheses
k-FWER
Generalized k = 1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
k = 2 T2D2,T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
k = 3 T2D2,T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
Augmented k = 1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
k = 2 T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
k = 3 T2D2,T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
FDP
Generalized 𝛾 = 0.1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
𝛾 = 0.2 T2D2,T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
𝛾 = 0.3 T2D2,T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
Augmented 𝛾 = 0.1 T2D3,T3D2,T3D3,T4D2,T4D3,T5D2,T5D3
𝛾 = 0.2 T2D3,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
𝛾 = 0.3 T2D2,T2D3,T3D1,T3D2,T3D3,T4D2,T4D3,T5D1,T5D2,T5D3
Abbreviations: FDP, false discovery proportion; FWER, familywise error rate.
k = 2, respectively. However, for 𝛾 = 0.3 the augmented procedure rejects two more hypotheses than the generalized
graphical procedure, while the latter only gives the same rejections as when 𝛾 = 0.2. This is because when 𝛾 = 0.3, kj > 2
in Algorithm 6 and there is no propagation of the significance levels.
6.2 The Pre-RELAX-AHF trial
Our second case study is a proof-of-concept trial called the Preliminary study of RELAXin in Acute Heart Failure
(Pre-RELAX-AHF).37 The trial compared three doses of relaxin against a placebo onmultiple biological endpoints related
to acute heart failure. Given that this was a proof-of-concept trial, less stringent error rates can be used when adjusting
for multiplicity.
One criterion for recommending the treatment for further testing is to show an effect on the majority of multiple
endpoints. Following Davison et al,38 we consider a subset of nine endpoints.We focus on the 30 μg/kg/day dose of relaxin
treatment, which showed efficacy on six of these endpoints when compared with placebo, using one-sided (uncorrected)
P-values with 𝛼 = .1. In what follows, we call the 30 μg/kg/day dose of relaxin treatment the experimental treatment, and
the placebo the control treatment.
Since the experimental treatment was declared efficacious in six out of nine endpoints in the pre-RELAX-AHF trial,
we consider a trial design where it is required to reject at least six out of nine hypotheses to declare success. Calling
these the primary hypotheses, we then add a hierarchical structure to this trial by supposing that we also test secondary
hypotheses if at least six out of the nine primary hypotheses were rejected. Hence, we have a family of primary hypotheses
1 = (H1,… ,H9) corresponding to testing the experimental treatment against the control across the nine endpoints, and
a family of secondary hypotheses 2.
We can represent this six out of nine gatekeeping procedure using entangled graphs, which were described
in Section 5.1. More precisely, we can define gatekeeping graphs for all
(
9
6
)
= 84 possible subsets of six primary
hypotheses and then entangle them.30 We perform a Holm procedure l on six hypotheses for each of the 84 sub-
sets of size 6, which we denote Jl, l = 1,… ,84. The full significance level 𝛼 is passed on to 2 if all six hypotheses in
1l = {Hi ∶ i ∈ Jl} are rejected. The testing procedure is given by the entangled graph  (c,l; l = 1,… , 84) where ci
= 1/84 for i = 1,… ,84.
This is equivalent to the following testing strategy: the usual Holm procedure is performed on the nine hypotheses
in 1 at level 𝛼 until any six of these hypotheses are rejected. The remaining primary and secondary hypotheses are then
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|I| Weight for each hypothesis in 1 Weight for 2 = {H10}
> 3 1/|I| 0
3 83/252 1/84
2 11/24 1/12
1 2/3 1/3
0 – 1
Note: Here |I| denotes the number of unrejected hypotheses in 1.
TABLE 4 Table of weights for the entangled
graph procedure used to analyse the trial based on
Pre-RELAX-AHF
tested using the weights given in Table 4, which depend on the number |I| of unrejected hypotheses in 1. For simplicity,
in what follows we suppose that 2 consists of a single hypothesis H10 (which could, eg, represent a composite safety
endpoint). We can then use the weights given in Table 4 in the k-FWER and FDP controlling graphical procedures.
In our simulation study, for the primary hypotheses 1 we follow Delorme et al39 and take the empirical means and
standard errors of the endpoints as the true parameter values for the experimental (E) and control (C) treatments. The
numerical values of the means 𝜇C, 𝜇E and standard deviations 𝜎C, 𝜎E are given in Appendix C. We assume that the
distributions of the observed means of the endpoints for the experimental and control treatments follow a multivari-
ate normal distribution: X
G
∼ N(𝜇G,ΣG) where G ∈ {C,E} and ΣG = diag(𝜎G)Σ(𝜌)diag(𝜎G). Here diag(𝜎G) is a diagonal
matrix with the ith diagonal element equal to 𝜇Gi , and Σ(𝜌) is a correlation matrix with ones on the diagonal and 𝜌 on all
off-diagonal terms. The test statistic for endpoint i is given by Ti = V̂ar(Xi
E
− Xi
C
)−1∕2Xi
E
− Xi
C
, which is compared with
a t-distribution. The estimator of the variance of the difference between the means, as well as the appropriate degrees of
freedom for the t-distribution are given by Delorme et al39 and implemented in their R package rPowerSampleSize.40
For the secondary hypothesis H10, for simplicity we assume that the test statistic T10 follows a normal distribution with
mean 3 and variance 1, and is independent of the test statistics for 1.
Table 5 gives the marginal power to reject each hypothesisH1,…H10, calculated using 104 trial replications, with 𝛼 =
.1 and 𝛿 = 1. The results show that in all scenarios, the augmented procedure has an equal or higher power to reject each
of the hypotheses H1,… ,H10. For the primary hypotheses H1,… ,H5 and H8, this is especially noticeable for the k-FWER
controlling procedures when k = 2 and k = 3. For hypothesis H9, the augmented procedures have a substantially higher
power compared with the generalized graphical procedure (except for when controlling the usual FWER). However, H9
is actually a true null hypothesis (with 𝜇C9 = 𝜇
E
9 = 0.07) and so this implies a higher type I error rate for H9 when using
the augmented procedure. In fact the type I error rate for H9 is below or equal to the nominal 10% in all scenarios for
the generalized graphical procedures. Finally, for the secondary hypothesis H10 (which has an initial weight of zero), we
see that the power decreases as k and 𝛾 increases for the k-FWER and FDP controlling generalized graphical procedures,
respectively (in particular, the power is only 6% when 𝛾 = 0.3 for the latter procedure). Again this shows that in contrast
to the augmented procedures, the generalized graphical approaches do not effectively propagate the significance levels
when there is a hierarchical structure in the hypotheses.
6.3 ATMOSPHERE study
Our final case study is motivated by the confirmatory ATMOSPHERE study41 in patients with heart failure. As described
in Maurer and Bretz,31 the trial compared three therapies: aliskiren monotherapy (A), enalapril monotherapy (E),
and aliskiren/enalapril combination therapy (C). This resulted in three single primary hypotheses (H1,H2,H3) and two
families of secondary hypotheses (4,5):
H1: nonsuperiority of C vs E
H2: inferiority of A vs E
H3: nonsuperiority of A vs E
4 = {H41,H42}: two secondary endpoints for comparing C vs E
5 = {H51,H52}: two secondary endpoints for comparing A vs E
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TABLE 5 Simulated marginal powers to reject hypotheses H1,… ,H10, with 𝛼 = .1 and the distribution of the test statistics for
1 = (H1,… ,H9) based on the Pre-RELAX-AHF trial reported by Teerlink et al37
Procedure Marginal power
H1 H2 H3 H4 H5 H6 H7 H8 H9 H10
k-FWER
k = 1 Generalized 95 89 72 78 85 100 100 62 6 64
Augmented 95 89 72 78 85 100 100 62 6 64
k = 2 Generalized 97 93 79 84 90 100 100 70 9 60
Augmented 98 97 90 92 95 100 100 87 65 84
k = 3 Generalized 98 95 81 86 92 100 100 73 10 42
Augmented 100 99 96 97 98 100 100 95 87 95
FDP
𝛾 = 0.1 Generalized 95 89 72 78 85 100 100 62 8 61
Augmented 95 89 72 78 85 100 100 63 38 65
𝛾 = 0.2 Generalized 95 92 78 83 89 100 100 70 9 50
Augmented 96 92 82 86 90 100 100 77 52 73
𝛾 = 0.3 Generalized 96 93 80 85 90 100 100 72 10 6
Augmented 97 94 86 88 92 100 100 83 58 83
Note: Results are based on 104 independent trial replications.
Abbreviations: FDP, false discovery proportion; FWER, familywise error rate.
F IGURE 4 The graph on the
left-hand side was used for the
ATMOSPHERE study, as presented in
Maurer and Bretz.31 The graph on the
right-hand side is the updated graph at
the start of step (ii) in the augmented
graphical approach for either k-FWER or
FDP control, after H2,H51, and H52 have
been rejected. FDP, false discovery
proportion; FWER, familywise error rate
The graph on the left-hand side in Figure 4 shows the graphical test procedure used in Maurer and Bretz31 to analyse
the trial. Note that if all individual null hypotheses in 4 or 5 are rejected, the local significance level is propagated to
the remaining hypotheses. For simplicity, we apply a Holm procedure within each of the two secondary families4 and
5. Following Reference 31, suppose we observe the (hypothetical) unadjusted P-values P1 = .1, P2 = .007, P3 = .05, P41
= .0015, P42 = .04, P51 = .0031, and P52 = .001.
Consider first controlling the k-FWER with k = 2 and 𝛼 = .025. For the augmented graphical approach (given in
Algorithm 1), in step (i) the Bonferroni-based graphical procedure for FWER control would reject H2, H51, and H52. The
updated graph used at the start of step (ii) is shown in the right-hand side of Figure 4, where 𝛼 has been replaced by 𝛿.
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Supposing that 𝛿 = 0.5, step (ii) of the algorithm rejectsH3. Since we have made one additional (augmented) rejection, at
this point we stop. As for the generalized graphical approach for k-FWER control (given in Algorithm 3), in step (ii) we
would only reject H2. Since the number of rejections |R| = k − 1, we stop at this point.
Now consider controlling the FDP with 𝛾 = 0.3. For the augmented graphical approach (given in Algorithm 4),
in step (i) we reject H2, H51, and H52 like before. In step (ii), we can reject one additional hypothesis, and hence we
reject H3 and then stop. Finally, for the generalized graphical approach (given in Algorithm 6), we first apply the usual
Bonferroni-based graphical procedure for FWER control, which rejects H2, H51, and H52. Since |R1| > 1/𝛾 − 1, we then
apply the 2-FWER procedure which (as above) only rejects H2. Since |R2| < 2/𝛾 − 1, we stop and only reject H2.
7 DISCUSSION
In this article, we have showed how to generalize the graphical approach of hypothesis testing3 so that the k-FWER or
the FDP can be controlled. By applying the methodology of Romano and Wolf18 and van der Laan,22 we have proposed
generalized and augmented graphical approaches for both k-FWER and FDP control (as well as an augmented procedure
for asymptotic FDR control). Crucially, these approaches respect the hierarchical structure of the underlying multiple
testing procedure given by the graphical weighting strategy. We have also applied the proposed graphical approaches to
three real-life case studies covering a broad range of clinical trial applications.
Our recommendation is that the augmented graphical approaches should be used instead of the generalized graphical
approaches. First, the generalized graphical approach for k-FWER control has the undesirable property that if a hypoth-
esisHj has fewer than k donors, its initial significance level will not increase. Hence, the generalized graphical approach
cannot effectively propagate the significance levels through the graph. The case studies in Section 6 show how this can
have a detrimental effect on the power of the generalized graphical approach—the power to reject hypotheses with fewer
than k donors can actually decrease as k increases. Since the generalized graphical approach for FDP control is based on
the generalized graphical approach for k-FWER control, a similar problem occurs.
By contrast, the augmented graphical approach is able to propagate significance levels to all hypotheses that have fewer
than k donors. As a consequence, the power of the augmented graphical approach for k-FWER control and FDP control
increases as k and 𝛾 increase (respectively). Importantly, in all of the case studies in Section 6, the augmented graphical
approach had a higher power (or rejected at least asmany hypotheses) comparedwith the generalized graphical approach.
These results are backed up by existing power comparisons for the generalized and augmentedHolm procedure16,27 when
testing a relatively small number of hypotheses.
The research for this article wasmotivated by clinical trial applications ranging from early to late drug development, as
illustrated by the case studies in Section 6. Outside of the context of clinical trials and the graphical weighting strategy of
Bretz et al,3 another area of application is testing hypotheses in a directed acyclic graph (DAG) for use in gene set analysis,
as proposed by Meijer and Goeman.42 The authors presented a top-down method that strongly controls the FWER, and
by considering the genes and gene sets as nodes in a DAG, the method allows testing for simultaneous testing of both
significant gene sets and individual genes. The testing procedure starts with an initial weight for each of the leaf nodes
(ie, nodes without any descendants), and an iterative weighting procedure is used to update the weights for all the other
nodes in the graph. These weights also satisfy the monotonicity condition given in Equation (2), and so suitably modified
versions of the augmented and generalized graphical approaches could be used in this setting.
As future work, it would be desirable to derive adjusted P-values for all of the proposed procedures, especially for
the augmented graphical approaches. This would involve extending the results of van der Laan,22 who showed how to
calculate adjusted P-values for their augmented approach. Finally, the initial motivation for this article came from con-
sidering the generalized closure principle,43 which was applied to derive stepup procedures for k-FWER control. The
usual graphical approach for FWER corresponds to defining a shortcut closed testing procedure.3 It would be interesting
to formalize a similar link between the generalized graphical approach for k-FWER control and the generalized closure
principle.
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APPENDIX A. GRAPHICAL WEIGHTING STRATEGY AND WEIGHTED BONFERRONI TEST
FOR FWER CONTROL
For a given index set J ⊆M, let Jc =M⧵J denote the set of indices not contained in J
Algorithm 7 (Graphical weighting strategy [24], Algorithm 1).
(i) Set I =M
(ii) Select j ∈ Jc and remove Hj
(iii) Update the graph:
I → I ⧵ {j}, Jc → Jc ⧵ {j}
wl(I) →
⎧⎪⎨⎪⎩
wl(I) + wj(I)gjl l ∈ I
0 otherwise
glh →
⎧⎪⎨⎪⎩
glh+gljgjh
1−gljgjl
l, h ∈ I, l ≠ h, gljgjl < 1
0 otherwise
(iv) If |Jc| ≥ 1, go to step (ii); otherwise set wl(J) = wl(I),l ∈ J and stop.
The weights wj(J),j ∈ J, generated by this procedure are unique,3 and in particular do not depend on which order the
hypotheses Hj,j ∈ Jc are removed in Algorithm 7.
Algorithm 8 (Bonferroni-based graphical test for FWER control [24], Algorithm 2).
(i) Set I =M
(ii) Select a j ∈ I such that pj ≤ wj(I)𝛼 and reject Hj; otherwise stop.
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(iii) Update the graph:
I → I ⧵ {j}
wl(I) →
{
wl(I) + wj(I)gjl l ∈ I
0 otherwise
glh →
⎧⎪⎨⎪⎩
glh+gljgjh
1−gljgjl
l, h ∈ I, l ≠ h, gljgjl < 1
0 otherwise
(iv) If |I| ≥ 1, go to step (ii); otherwise stop.
The final decisions of the algorithm do not depend on which order the hypotheses are rejected. For example, step (ii)
above could be replaced by choosing j = argmini∈I{pi∕wi(I)}.
Algorithm 9 (Adjusted P-values [3], Algorithm 2).
(i) Set I =M and pmax = 0
(ii) Let j = argmini∈Ipi∕wi(I)
(iii) Calculate padjj = max{pj∕wj(I), pmax} and set pmax = p
adj
j .
(iv) Update the graph:
I → I ⧵ {j}
wl(I) →
{
wl(I) + wj(I)gjl l ∈ I
0 otherwise
glh →
⎧⎪⎨⎪⎩
glh+gljgjh
1−gljgjl
l, h ∈ I, l ≠ h, gljgjl < 1
0 otherwise
(v) If |I| ≥ 1, go to step (ii); otherwise stop.
(vi) Reject all hypotheses Hj with padjj ≤ 𝛼
APPENDIX B. FURTHER RESULTS ON THE GENERALIZED GRAPHICAL APPROACH
B.1 Streamlined and operative versions of the generalized graphical approach
Apart from special cases, applying the generalized graphical approach given in Algorithm 3 can be computationally
intensive for larger values of m, particularly since the weights wi(K) need to be calculated using Algorithm 7. For large
values of m, we can directly apply the streamlined version of the general stepdown method for controlling the k-FWER
in Romano and Wolf [18, Algorithm 4.2] to give a streamlined version of Algorithm 3. The way this version works is to
avoid minimizing over all subsets of size k − 1 of previously rejected hypothesis, and only consider the least significant k
− 1 of the previous rejections. Note that this only gives asymptotic control of the k-FWER (as the sample size of the trial
increases).
Algorithm 10 (Streamlined graphical approach for k-FWER control). Given an index set R of rejected hypotheses, let p1:R
≤ p2:R ≤… ≤ p|R|:R denote the ordered P-values, with corresponding hypotheses H1:R,H2:R,… ,H|R|:R. Denote by {r1,… ,r|R|} the
permutation of {1,… ,|R|} that gives this ordering, so that p1∶R = pr1 ,… , p|R|∶R = pr|R| . The streamlined algorithm is the same
as Algorithm 3, except that at step (iv) we now reject any Hi, i ∈ I for which pi ≤ wi(K)k𝛼, where K = I∪{r|R| − k + 2,… ,r|R|}.
The streamlined version only gives asymptotic control of the k-FWER, but involves nominimization over any subsets.
In order to get closer to the original, exact algorithm while still retaining computational feasibility, as a compromise we
can use the operative method proposed in Romano andWolf [18, Remark 3.3]. Consider that to compute the critical value
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in step (iv) of Algorithm 3, one has to evaluate
( |R|
k−1
)
weights in order to choose the minimum. The operative method
maximizes over subsets not necessarily of the entire index set R of previously rejected hypotheses, but only for some
number B least significant hypotheses so far. More precisely, we have the following algorithm:
Algorithm 11 (Operative graphical approach for k-FWER control). Pick a user-specified number Nmax and let B be the
largest integer for which
(
B
k−1
)
≤ Nmax. The operative method is the same as Algorithm 3, except that step (iv) rejects any Hi,
i ∈ I for which
pi ≤ min
J⊆{rmax{1,|R|−B+1},…,r|R|},|J|=k−1{wi(K) ∶ K = I ∪ J}k𝛼
When B ≥ |R| we maximize over all subsets of R of size k − 1 like in the original algorithm, while the streamlined
algorithm is a special case of the operative method where Nmax = 1 and hence B = k − 1.
B.2 Examples of the generalized graphical approach
Example 5 (Generalized Weighted Bonferroni:). Suppose each vertex on the graph is unconnected, that is, gij = 0 for
all i,j ∈ M. Algorithm 7 implies that wj(J) = wj(M), j ∈ J for all J ⊆ M. Hence the inequality in step (iv) of Algorithm 3
is simply pi ≤ wi(M)k𝛼 and so there is no further testing after step (ii), unless 𝛿 > 0 and |R| < k − 1. Thus when 𝛿 = 0,
Algorithm 3 is exactly the same as the generalized weighted Bonferroni procedure in Section 2 with wi = wi(M).
Example 6 (Generalized Holm:). To represent the Holm procedure with m hypotheses, we set the initial weights
wi(M) = 1/m and gij = 1/(m − 1) for all i, j ∈ M, i ≠ j. Hence using Algorithm 7, we have wi(I) = 1/|I| for all i ∈ I and
I ⊆M, and the inequality in step (iv) of Algorithm 3 is simply
pi ≤
k𝛼|I| + k − 1 = k𝛼m + k − |R| − 1
For 𝛿 = 0, this gives identical rejections to the generalized Holm procedure as given in Lehmann and Romano.12
Example 7 (Hierarchical testing: fixed sequence test and fallback procedure). In a fixed sequence test, the hypotheses
are tested in a prespecified order. This allows each hypothesis to be tested at the full level 𝛼 while controlling the FWER,
with the proviso that if any hypothesis is not rejected then no further testing is allowed. Suppose the prespecified ordering
for testingm hypotheses isH1→H2→…→Hm. Hence, we have gij = 1 for i = 1,… ,m − 1 if j = i + 1 and gij = 0 otherwise.
If we follow the usual fixed sequence test and setw1(M)= 1 andwi(M)= 0, i= 1,… ,m− 1, then onlyH1 can be rejected
in step (ii) of the Algorithm 3 and hence the algorithm will never proceed to step (iv) since |R| < k. Hence, a more natural
generalization of the fixed sequence test is to set the initial weights aswi(M)= 1/k for i= 1,… ,k andwi(M)= 0 otherwise.
This means that the first k hypotheses will be tested at full level 𝛼. However, assume that the first k hypotheses are all
rejected (otherwise we proceed to the subprocedure of step (iii) and can only reject up to the first k − 1 hypotheses). Since
wi({1,… ,k − 1,k + 1,… ,i,… ,m}) = 0 for i = k + 1,… ,m, step (iv) of the algorithm implies that no further hypotheses can
then be rejected. For k > 1, this generalization of the fixed sequence test has the undesirable property that only the first k
hypotheses can ever be tested, even when using the subprocedure of step (iii) with 𝛿 > 0.
A similar issue occurs when generalizing the fallback procedure,44 which is a modification of the fixed sequence
procedure where the initial weightswi(M) > 0 for all i ∈M. Applying Algorithm 3, suppose (without loss of generality, by
relabeling the hypothesis labels) that the hypothesesH1,… ,Hk are all rejected at step (ii). However, sincewi(I ∪ {1,… , k −
1}}) = wi(M) for all i ∈ I and I ⊆ {k + 1,… ,m}, step (iv) implies that the hypotheses Hi, i = k + 1,… ,m, are also tested at
significance level wi(M)k𝛼. So for k > 1, this generalization of the fallback procedure has the undesirable property that
rejecting hypotheses does not lead to an increase in the significance levels of the remaining hypotheses, except via the
subprocedure of step (iii) when 𝛿 > 0 (but even then, the propagation is limited to at most k − 1 hypotheses).
Example 8 (Hypotheses with fewer than k donors:). We can generalize the previous example to any graph where any
hypothesis has fewer than k donors, where the donors of a hypothesis Hj are the hypotheses that donate (or propagate)
their significance levels toHj if they are rejected. More formally, we denote the donors of hypothesisHj by do(Hj)= {Hi:gij
> 0}. Note that two hypotheses Hi and Hj can be donors to each other.
If a hypothesis Hj in a graph has fewer than k donors, then applying the generalized graphical approach has the
undesirable property that the initial significance level forHj can never increase, even if all its donors are rejected (except
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for up to k − 2 hypotheses via the subprocedure in step (iii)). To see this, suppose 𝛿 = 0 and all donors of Hj have been
rejected (and |R| ≥ k, or else there is no propagation). In step (iv) of Algorithm 3, since |do(Hj)| ≤ k − 1 then
min
J⊆R,|J|=k−1{wi(K) ∶ K = I ∪ J}k𝛼 ≤ wi
(
I ∪ do(Hj)
)
k𝛼 = wi(M)k𝛼.
Hence Hj is tested using the initial weights in step (iv). In particular, this means that if a hypothesis with fewer than k
donors has an initial weight of zero, then it can never be rejected (except possibly via the subprocedure in step (iii)). This
can be an undesirable property to have in a testing procedure which has a hierarchical structure, as we will see further in
the case studies in Section 6.
As an example, consider the graph for the diabetes trial shown in Figure 1, and supposewewish to control the k-FWER
for k = 2. Since the secondary hypothesesH3 andH4 only have one donor each (hypothesesH1 andH2, respectively) and
start with a weight of zero, they will never be rejected even if more than one of the primary hypotheses H1 and H2 are
rejected.
APPENDIX C. PARAMETER VALUES FOR THE PRE-RELAX-AHF TRIAL
In our simulation study, for the primary hypotheses H1,… ,H9 we take the empirical means and standard errors of the
endpoints as the true parameter values for the experimental (E) and control (C) treatments. The numerical values of the
means 𝜇C, 𝜇E and standard deviations 𝜎C, 𝜎E are given in Delorme et al39 and reproduced below:
𝜇C = (0.23, 1679, 0.79,−12, 44.2, 0.828, 0.857, 0.13, 0.07)
𝜇E = (0.4, 2567, 0.88,−10.2, 47.9, 0.974, 1, 0.21, 0.07)
𝜎C = (
√
0.23(1 − 0.23), 2556,
√
0.79(1 − 0.79), 7.3, 14.2,
√
0.828(1 − 0.828),
√
0.857(1 − 0.857),√
0.13(1 − 0.13),
√
0.07(1 − 0.07))
= (0.421, 2556, 0.407, 7.3, 14.2, 0.377, 0.350, 0.336, 0.255)
𝜎E = (
√
0.4(1 − 0.4), 2898,
√
0.88(1 − 0.88), 6.1, 10.1,
√
0.974(1 − 0.974), 10−12,
√
0.21(1 − 0.21),√
0.07(1 − 0.07))
= (0.490, 2898, 0.325, 6.1, 10.1, 0.159, 10−12, 0.407, 0.255)
